Matthew S. Johnson, MD, FSIR / Richard S. Finn, MD - At the Nexus of Locoregional and Systemic Liver Cancer Therapy: A Multidisciplinary Tumor Board on Improving Outcomes in Intermediate to Advanced HCC

Chia sẻ

Manage episode 294796781 series 2771425
Thông tin tác giả PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education được phát hiện bởi Player FM và cộng đồng của chúng tôi - bản quyền thuộc sở hữu của nhà sản xuất (publisher), không thuộc về Player FM, và audio được phát trực tiếp từ máy chủ của họ. Bạn chỉ cần nhấn nút Theo dõi (Subscribe) để nhận thông tin cập nhật từ Player FM, hoặc dán URL feed vào các ứng dụng podcast khác.
Go online to to view the activity, download slides and practice aids, and complete the post-test to earn credit. With several available treatment modalities, hepatocellular carcinoma (HCC) requires a multidisciplinary approach that is based on disease stage and patient factors. The role of the interventional radiologist, always vital in managing intermediate-stage disease via locoregional approaches, has become increasingly more important in the treatment of advanced-stage disease, as oncologists, interventional radiologists, and transplant hepatologists work together to improve patient outcomes. Join PeerView’s multidisciplinary team of liver cancer experts for an in-depth analysis of the latest data on approved and emerging systemic treatment options for HCC and recent evidence on locoregional and multimodal approaches in various treatment settings. Through an engaging “tumor board” discussion, the expert panel will draw upon their clinical experience to provide guidance on optimal selection and transition between locoregional and systemic therapies, with a focus on guideline recommendations, underlying liver disease, biomarker information, and other patient-related factors. Upon completion of this activity, participants should be better able to: Describe the safety and efficacy of available systemic treatment options, including multikinase inhibitors, anti-angiogenic agents, and checkpoint inhibitors alone and in combinations, across multiple lines of therapy for patients with advanced HCC, Review the latest evidence and ongoing trials on established and emerging combination approaches (eg, dual immune checkpoint blockade, immunotherapy plus targeted therapy, systemic agents plus locoregional therapy) for patients with intermediate- and advanced-stage HCC, Develop safe and effective multidisciplinary treatment plans for patients with intermediate- and advanced-stage HCC that are based on expert guidance, available evidence, underlying liver disease factors, biomarker information, and recommendations on timely transitions from locoregional to systemic options.

278 tập